Pegylated Liposomal Doxirubicin in Cutaneous T Cell Lymphoma (2011 ASH Conference)

VIDEO | 02:00

Pegylated Liposomal Doxirubicin (PLD) is approved for treatment of Kaposi’s sarcoma and concentrates highly in the skin. To clarify the true overall response for PLD and to assess whether the overall response and remission durations can be improved by sequential bexarotene following PLD, a multi-institutional phase II trial was undertaken for patients with advanced stage/refractory cutaneous T cell lymphoma.

Medical oncologist David Straus discusses how sequential bexarotene did not increase the response rate or duration.